Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group. Ardavanis A, et al. Among authors: vamvakas l. Cancer Chemother Pharmacol. 2006 Dec;58(6):742-8. doi: 10.1007/s00280-006-0236-3. Epub 2006 May 23. Cancer Chemother Pharmacol. 2006. PMID: 16718470 Clinical Trial.
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A, Georgoulias V, Mavroudis D, Souglakos J. Emmanouilides C, et al. Among authors: vamvakas l. BMC Cancer. 2007 May 30;7:91. doi: 10.1186/1471-2407-7-91. BMC Cancer. 2007. PMID: 17537235 Free PMC article. Clinical Trial.
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulias V, Mavroudis D. Kalbakis K, et al. Among authors: vamvakas l. Cancer Chemother Pharmacol. 2008 Aug;62(3):449-56. doi: 10.1007/s00280-007-0624-3. Epub 2007 Oct 25. Cancer Chemother Pharmacol. 2008. PMID: 17960381
Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
Gioulbasanis I, Saridaki Z, Kalykaki A, Vamvakas L, Kalbakis K, Ignatiadis M, Amarantidis K, Kakolyris S, Georgoulias V, Mavroudis D. Gioulbasanis I, et al. Among authors: vamvakas l. Anticancer Res. 2008 Sep-Oct;28(5B):3019-25. Anticancer Res. 2008. PMID: 19031950 Free article. Clinical Trial.
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A, Georgoulias V, Mavroudis D. Bozionelou V, et al. Among authors: vamvakas l. Cancer Chemother Pharmacol. 2009 Sep;64(4):785-91. doi: 10.1007/s00280-009-0928-6. Epub 2009 Jan 22. Cancer Chemother Pharmacol. 2009. PMID: 19159931 Clinical Trial.
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V. Katopodis O, et al. Among authors: vamvakas l. Cancer Chemother Pharmacol. 2011 Feb;67(2):361-8. doi: 10.1007/s00280-010-1329-6. Epub 2010 Apr 29. Cancer Chemother Pharmacol. 2011. PMID: 20428874 Clinical Trial.
83 results